These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 22396645)

  • 1. Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox.
    Kremer M; Suezer Y; Volz A; Frenz T; Majzoub M; Hanschmann KM; Lehmann MH; Kalinke U; Sutter G
    PLoS Pathog; 2012; 8(3):e1002557. PubMed ID: 22396645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.
    Volz A; Langenmayer M; Jany S; Kalinke U; Sutter G
    J Virol; 2014 Sep; 88(18):10946-57. PubMed ID: 25008931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.
    Volz A; Jany S; Freudenstein A; Lantermann M; Ludwig H; Sutter G
    Viruses; 2018 Jan; 10(1):. PubMed ID: 29300297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
    McCurdy LH; Rutigliano JA; Johnson TR; Chen M; Graham BS
    J Virol; 2004 Nov; 78(22):12471-9. PubMed ID: 15507634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
    Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
    J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host.
    Belyakov IM; Isakov D; Zhu Q; Dzutsev A; Klinman D; Berzofsky JA
    J Immunol; 2006 Nov; 177(9):6336-43. PubMed ID: 17056564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.
    Drexler I; Staib C; Kastenmuller W; Stevanović S; Schmidt B; Lemonnier FA; Rammensee HG; Busch DH; Bernhard H; Erfle V; Sutter G
    Proc Natl Acad Sci U S A; 2003 Jan; 100(1):217-22. PubMed ID: 12518065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.
    Snyder JT; Belyakov IM; Dzutsev A; Lemonnier F; Berzofsky JA
    J Virol; 2004 Jul; 78(13):7052-60. PubMed ID: 15194781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term recall of memory CD8 T cells in mice to first and third generation smallpox vaccines.
    Green S; Ennis FA; Mathew A
    Vaccine; 2011 Feb; 29(8):1666-76. PubMed ID: 21195803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
    Parrino J; McCurdy LH; Larkin BD; Gordon IJ; Rucker SE; Enama ME; Koup RA; Roederer M; Bailer RT; Moodie Z; Gu L; Yan L; Graham BS;
    Vaccine; 2007 Feb; 25(8):1513-25. PubMed ID: 17126963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge.
    Jones DI; McGee CE; Sample CJ; Sempowski GD; Pickup DJ; Staats HF
    Clin Vaccine Immunol; 2016 Jul; 23(7):648-51. PubMed ID: 27146001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
    Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
    PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
    McCurdy LH; Larkin BD; Martin JE; Graham BS
    Clin Infect Dis; 2004 Jun; 38(12):1749-53. PubMed ID: 15227622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
    Wyatt LS; Earl PL; Eller LA; Moss B
    Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
    Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
    Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunology of smallpox vaccines.
    Kennedy RB; Ovsyannikova IG; Jacobson RM; Poland GA
    Curr Opin Immunol; 2009 Jun; 21(3):314-20. PubMed ID: 19524427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective CD8+ T cell memory without help.
    Fang M; Sigal LJ
    Oncotarget; 2015 Oct; 6(30):28529-30. PubMed ID: 26356572
    [No Abstract]   [Full Text] [Related]  

  • 20. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines.
    Tscharke DC; Karupiah G; Zhou J; Palmore T; Irvine KR; Haeryfar SM; Williams S; Sidney J; Sette A; Bennink JR; Yewdell JW
    J Exp Med; 2005 Jan; 201(1):95-104. PubMed ID: 15623576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.